AAN 2026 18 - 22 April 2026

Results from evoke and evoke+: Two phase 3, randomised, placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer’s disease

Authors :

Jeffrey L. Cummings¹, Alireza Atri^2–4, Howard H. Feldman⁵, Mary Sano^6,7, Henrik Zetterberg⁸, Filip K. Knop⁹, Peter Johannsen⁹, Teresa León⁹, Rikke Mortensen Abschneider⁹, Philip Scheltens^10,11

Affiliations

View Details Hide Details

Download .PDF

Keywords

Neurodegenerative diseases

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Results from evoke and evoke+: Two phase 3, randomised, placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer’s disease